Company Overview and News

 
Director, buy-back activity on Hong Kong exchange plunges due to short trading week

2017-10-08 scmp
The director and buy-back activity plunged based on filings on the Hong Kong stock exchange during the holiday shortened week of October 3 to 6. A total of 30 companies recorded 142 buys worth HK$284 million (US$36.4 million) versus seven firms with 14 disposals worth HK$62 million.

 
Greenland sells management arm to rival developer for US$146m

2017-07-03 scmp
The two developers will strengthen property management co-operation after the sale. Greenland will offer up to 10 million sq m of properties for Agile to manage

 
Stock sales put the spotlight on Huishan Dairy chairman

2017-03-26 scmp
The buying by directors rose for the sixth straight week based on filings on the Hong Kong stock exchange from March 20 to 24 with 21 companies that recorded 77 purchases worth HK$99.7 million. The number of firms and trades were sharply up from the previous week’s 15 companies and 61 purchases. The buy value, however, was down from the previous week’s acquisitions worth HK$139 million. The selling, on the other hand, rose for the second straight week with 10 companies that recorded 55 disposals worth HK$344 million.

 
Chinese developers scramble to issue panda bonds

2016-04-05 scmp
Real estate firms are poised to become the pioneers in China’s panda bond market as part of their efforts to diversify financing channels and avoid foreign-exchange risks.

 
Markets face $1tn Asian EM debt worries

2016-02-29 ft
Highly indebted companies across Asia are closely watching the direction of the US dollar. A case in point is Agile Property Holdings and the property developer must generate cash to repay its HK$3bn debt over 2016 while contending with flat sales

 
China stocks head for biggest loss in month as small caps tumble

2016-02-25 themalaymailonline
SHANGHAI, Feb 25 — China’s stocks tumbled the most in a month, led by technology and small-company shares, as surging money- market rates signal tighter liquidity and concern grew recent gains were overdone relative to the outlook for the economy

 
China stocks tumble on profit-taking ahead of G20 meeting; HK also down

2016-02-25 thehindubusinessline
China stocks fell more than 3 per cent on Thursday, led by small-caps, as investors to

 
China stocks tumble on profit-taking ahead of G20 meeting; Hong Kong also down

2016-02-25 financialexpress
The blue-chip CSI300 index tumbled 3.4 percent to 3,005.23 points by lunch time, while the Shanghai Composite Index lost 3.6 percent to 2,823.06.

 
China stocks tumble ahead of G20 meeting

2016-02-25 news.theage.com.au
Stocks in China and Hong Kong are lower as investors await developments from a G20 meeting.

 
China stocks tumble ahead of G20 meeting

2016-02-25 news.smh.com.au
Stocks in China and Hong Kong are lower as investors await developments from a G20 meeting.

 
China’s stocks fall as technology, industrial companies retreat

2016-02-25 themalaymailonline
SHANGHAI, Feb 25 — Chinese stocks fell amid speculation recent gains for the benchmark index were overdone relative to the outlook for the economy and earnings. The Shanghai Composite Index slid 1.1 per cent to 2,897.53 at 9.52am , led by

Related Articles

HRTX : Heron Therapeutics Analysis and Research Report

13h - Asif

Overview Heron is a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments that address some of the most important unmet patient needs. Heron Therapeutics is developing novel, patient-focused solutions that apply its innovative science and technologies to already approved pharmacological agents for patients suffering from cancer or pain. On August 9, 2016, its first commercial product, SUSTOL, was approved by the FDA. The company developed SUSTOL for the prevention of chemotherapy-induced nausea and vomiting (“CINV”). SUSTOL is indicated, in combination with other antiemetics, in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy (“MEC”) or anthracycline and cyclophosphamide (“AC”) combination chemotherapy regimens. The company commenced commercial sales of SUSTOL in the U.S. in October 2016. On November 9, 2017...

ACIA: Acacia Communications Analysis and Research Report

13h - Asif

Overview The company's mission is to deliver high-speed coherent optical interconnect products that transform communications networks, relied upon by cloud infrastructure operators and content and communication service providers, through improvements in performance and capacity and reductions in associated costs. By converting optical interconnect technology to a silicon-based technology, a process the company refer to as the siliconization of optical interconnect, the company believe Acacia Communications is leading a disruption that is analogous to the computing industry’s integration of multiple functions into a microprocessor. The company's products include a family of low-power coherent digital signal processor application-specific integrated circuits, or DSP ASICs, and silicon photonic integrated circuits, or silicon PICs, which Acacia Communications has integrated into families of optical interconnect modules with transmission speeds ranging from 100 to 400 gigabits per ...

ANTH: Anthera Pharmaceuticals Analysis and Research Report

2018-05-21 - Asif

Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...